Literature DB >> 6228352

T cell subsets in patients with rheumatoid arthritis: reduction of cells with Leu 2A phenotype in patients with serum IgG immunocomplexes.

M V Queiros, B Rocha.   

Abstract

The distribution of T cell subsets in the peripheral blood lymphocytes of 50 patients with rheumatoid arthritis (RA) and 28 controls was evaluated using the monoclonal anti-human T cell antibodies, alpha-Leu 1, alpha-Leu 2a and alpha-Leu 3a. A reduced number of cells with Leu 2a phenotype was observed in the group of patients with active RA. When patients were classified according to both disease activity and the presence of IgG or IgM immunocomplexes, a good correlation was observed between reduced Leu 2a+ numbers and the presence of IgG immunocomplexes. Patients without serum IC had normal numbers of Leu 2a T cells, independently of the activity of the disease. The significance of these results to the understanding of the aetiopathogenesis of RA is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228352      PMCID: PMC1535873     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  Relations between Fc receptor function and locomotion in human lymphocytes.

Authors:  J M Shields; P C Wilkinson
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

2.  Rheumatoid synovial lymphocytes lack concanavalin-A-activated suppressor cell activity.

Authors:  C Chattopadhyay; H Chattopadhyay; J B Natvig; O J Mellbye
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

Review 3.  Hunan T cell subpopulations in normal and pathologic conditions.

Authors:  L Moretta; M C Mingari; A Moretta
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

4.  Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis.

Authors:  G R Burmester; J R Kalden; H H Peter; I Schedel; P Beck; A Wittenborg
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

5.  Enumeration of T lymphocytes subsets in autoimmune disease using monoclonal antibodies.

Authors:  F Raeman; W De Cock; T De Beukelaar; J De Cree; H Verhaegen
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

6.  [Fc-gamma-receptor cells and rheumatoid arthritis].

Authors:  J Sany; J Clot; M Andary; B Paradis; H Serre
Journal:  Rev Rhum Mal Osteoartic       Date:  1978-05

7.  Suppressor T cell dysfunction and anti-suppressor cell antibody in active early rheumatoid arthritis.

Authors:  N I Abdou; H B Lindsley; L S Racela; E Pascual; K M Hassanein
Journal:  J Rheumatol       Date:  1981 Jan-Feb       Impact factor: 4.666

8.  Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents.

Authors:  E M Veys; P Hermanns; G Goldstein; P Kung; J Schindler; J Van Wauwe
Journal:  Int J Immunopharmacol       Date:  1981

9.  T gamma lymphocytes of peripheral blood and synovial fluid in rheumatoid arthritis: quantitative determination and qualitative analysis.

Authors:  A Mathieu; M C Mereu; L Pisano
Journal:  Arthritis Rheum       Date:  1981-05

10.  The adherence of human Fc receptor-bearing lymphocytes to antigen-antibody complexes. II. Morphologic alterations induced by the substrate.

Authors:  E Alexander; P Henkart
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

View more
  2 in total

1.  The immunological consequences of gold therapy: a prospective study in patients with rheumatoid arthritis.

Authors:  J Hassan; J Hanly; B Bresnihan; C Feighery; C A Whelan
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

2.  Phenotypes of peripheral blood T lymphocytes in rheumatoid arthritis and juvenile rheumatoid arthritis. Findings in patients with varying disease activity and clinical subgroups.

Authors:  J Thoen; O Førre
Journal:  Clin Rheumatol       Date:  1988-06       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.